Europe's regulator says Mounjaro can be used for sleep apnea without a new approval

The European Medicines Agency has told Eli Lilly that it can update Mounjaro's product label to show a benefit in treating obstructive sleep apnea (OSA) without requiring a separate approval for the condition ^[1]. Lilly had sought EU approval to treat moderate to severe OSA in patients with obesity, but the EMA said a standalone approval was not needed because the sleep disorder is closely tied to obesity itself ^[1].

Lilly said the two conditions overlap heavily, noting that about 58% of people with moderate to severe OSA also carry excess weight ^[1]. That overlap is central to the EMA's reasoning: since Mounjaro (tirzepatide) is already approved in Europe for obesity and type 2 diabetes, and OSA is closely linked to obesity, the agency treated the sleep apnea benefit as part of the drug's existing use rather than a new therapeutic area ^[1].

The evidence behind the label update comes from two clinical trials involving 469 participants, which Lilly reported in April. In those trials, tirzepatide cut the frequency of irregular breathing episodes by as much as 63% ^[1]. Lilly was separately pursuing approval for tirzepatide in sleep apnea patients in the United States, a process that follows a different regulatory track ^[1]. The source does not specify the exact date of the eventual US approval beyond noting it came about a week after the EMA's decision ^[1].

Obstructive sleep apnea is common, affecting roughly 1 billion people worldwide, according to a 2019 study cited in the Reuters report ^[1]. Standard treatments include CPAP machines, which require wearing a mask during sleep, surgery, and weight loss ^[1]. Lilly and Novo Nordisk have both been working to show that their obesity drugs offer benefits beyond weight loss, since approval for additional conditions could boost demand at a time when interest in these drugs is already high ^[1].

Why it matters for patients

For people in Europe already using Mounjaro for obesity, this decision means the drug's label can now reflect a sleep apnea benefit without patients needing a new, separate approval process to access that use ^[1]. That is different from the situation in the United States, where Lilly pursued a standalone approval specifically for sleep apnea, a process that came about a week after the EMA's decision ^[1].

The distinction matters because regulatory pathways affect how a drug can be marketed and who a doctor might consider prescribing it to. In the EU, the EMA treated the sleep apnea effect as an extension of the drug's known obesity benefit rather than as a freestanding new indication ^[1]. In the US, a separate approval process creates a distinct indication on the label. The sources do not detail how this difference in regulatory routes might affect insurance coverage or prescribing patterns in either region, so those practical effects are not yet known from the available reporting.

Patients considering treatment for sleep apnea related to obesity may also be weighing existing options such as CPAP machines or surgery ^[1]. The trial data showing up to a 63% reduction in irregular breathing episodes come from studies with 469 total participants, a relatively modest size for drawing broad conclusions about long-term outcomes ^[1].

What happens next

The EMA's decision was announced on December 13, 2024 ^[1]. Lilly's separate US approval for sleep apnea came about a week later, according to the Reuters report, though the exact American approval date is not stated in the source ^[1]. Further details on how the EU label change will be implemented, or how the US indication differs in scope, are not covered in the available reporting and remain unknown for now.